Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 4/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302953 | 0.84 | CARM1 (0.52) | CARM1PRMT6CHRM1SCN9ASLC6A4 | |
| SCHEMBL2299162 | 0.83 | CARM1 (0.56) | CARM1PRMT6CHRM1SCN9ASLC6A4 | |
| SCHEMBL3126417 | 0.82 | CARM1 (0.58) | CARM1PRMT6ALDH1A1 | |
| SCHEMBL2301027 | 0.82 | CARM1 (0.56) | CARM1PRMT6CHRM1SLC6A4ALDH1A1 | |
| SCHEMBL2296456 | 0.81 | CARM1 (0.54) | CARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL13734341 | 0.81 | CARM1 (0.55) | CARM1PRMT6CHRM1SLC6A4ALDH1A1 | |
| SCHEMBL2056157 | 0.79 | CARM1 (0.71) | CARM1PRMT6CHRM1SCN9ASLC6A4 | |
| SCHEMBL2088681 | 0.79 | SCN9A (0.45) | CARM1PRMT6SCN9AALDH1A1TSHR | |
| SCHEMBL3121802 | 0.79 | NAAA (0.42) | CARM1PRMT6 | |
| SCHEMBL2298969 | 0.79 | EPHX2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | CARM1 3558/4885PRMT6 3503/4885CHRM1 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.